Shridhar C. Ghagane^1,3, Shadab Rangrez³, R.B. Nerli^2,3, Madhukar L. Thakur^4,6, Leonard G. Gomella^5,6

Canadian Journal of Urology, Vol.31, No.3, pp. 11892-11896, 2024

Abstract Introduction: Prostate cancer is the second most common malignancy in men worldwide. Genomic VPAC receptors are expressed on malignant prostate cancer cells and can be targeted and imaged optically by a peptide labeled fluorophore. The objective of our study was to assess the feasibility of detecting cancer of the prostate using a voided urine sample.
Materials and methods: Patients ≥ 40 years old, with lower urinary tract symptoms and serum PSA > 4 ng/ mL formed the study group. The first 50 mL of voided urine sample was collected and processed. The cells that were shed in… More >

Nikola C. Teslovich¹, Peter Elliott², Christopher S. Elliott²

Canadian Journal of Urology, Vol.31, No.3, pp. 11886-11891, 2024

Abstract Introduction: To define the smallest prostate needle biopsy (PNB) template necessary for accurate tissue diagnosis in men with markedly elevated PSA while decreasing procedural morbidity.
Materials and methods: We performed a chart review of 80 men presenting with a newly elevated PSA > 100 ng/mL who underwent biopsy (PNB or metastatic site). For patients who underwent a full 12-core biopsy, simulated templates of 2- to 10-cores were generated by randomly drawing subsets of biopsies from their full-template findings. Templates were iterated to randomize core location and generate theoretical smaller template outcomes. Simulated biopsy results were compared to… More >

Bassem Toeama¹, Nathan Perlis², Paul Grootendorst¹, William Orovan³, Emmanuel Papadimitropoulos^1,4

Canadian Journal of Urology, Vol.31, No.4, pp. 11963-11970, 2024

Abstract Introduction: Prostate cancer is the third leading cause of death from cancer among Canadian men. High intensity focused ultrasound (HIFU) is a novel approach for primary treatment of localized prostate cancer. Little is known, however, about its costs. We aimed to collect the direct costs and health-related quality of life (HRQoL) data of HIFU in primary treatment of localized low and intermediate risk prostate cancer in Ontario.
Materials and methods: We collected direct costs and HRQoL data of 20 patients with localized low or intermediate risk prostate cancer who received whole gland HIFU at a privately owned… More >

Snir Dekalo^1,2, Ohad Mazliah², Eyal Barkai^1,2, Yuval Bar-Yosef^1,2, Haim Herzberg^1,2, Tomer Bashi^1,2, Ibrahim Fahoum^2,3, Sophie Barnes^2,4, Mario Sofer^1,2, Ofer Yossepowitch^1,2, Gal Keren-Paz^1,2, Roy Mano^1,2

Canadian Journal of Urology, Vol.31, No.4, pp. 11955-11962, 2024

Abstract Introduction: Most men diagnosed with very-low and low-risk prostate cancer are candidates for active surveillance; however, there is still a misclassification risk. We examined whether PI-RADS category 4 or 5 combined with ISUP 1 on prostate biopsy predicts upgrading and/ or adverse pathology at radical prostatectomy.
Materials and methods: A total of 127 patients had ISUP 1 cancer on biopsy after multiparametric MRI (mpMRI) and then underwent radical prostatectomy. We then evaluated them for ISUP upgrading and/or adverse pathology on radical prostatectomy.
Results: Eight-nine patients (70%) were diagnosed with PI-RADS 4 or 5 lesions. ISUP upgrading was significantly… More >

Judd W. Moul

Canadian Journal of Urology, Vol.31, No.4, pp. 11941-11942, 2024

Abstract This article has no abstract. More >

Bárbara Vieira Lima Aguiar Melão¹, Sabrina Thalita dos Reis Faria², Kátia Ramos Moreira Leite², Ruan César Aparecido Pimenta², Miguel Srougi¹, Alberto Azoubel Antunes¹

Canadian Journal of Urology, Vol.31, No.4, pp. 11931-11940, 2024

Abstract Introduction: Prostate cancer has a variable natural history and, despite the existence of biochemical recurrence (BCR) predictors, they are still limited in predicting outcomes. The role of testosterone in advanced prostate cancer is well known, however its role in localized prostate cancer is still uncertain. In the present study, we evaluated the relationship of testosterone levels and androgen receptor (AR) expression with oncological and functional outcomes, in patients undergoing radical retropubic prostatectomy (RRP).
Materials and methods: Through a retrospective study, patients who underwent RRP, who had at least two preoperative total testosterone dosages, were analyzed and compared… More >

James Wysock^1,*, Jesse Persily^1,*, Angela Tong², Eli Rapoport¹, Ben Zaslavsky¹, Majlinda Tafa¹, Herbert Lepor¹

Canadian Journal of Urology, Vol.31, No.5, pp. 11986-11991, 2024

Abstract Introduction: Local disease recurrence following focal therapy (FT) for prostate cancer may be due to failure to eradicate focal disease or development of disease in the untreated prostate (in- and out-of-field recurrences). Several studies suggest in-field contrast enhancement (CE) on post treatment multi-parametric (mp) MRI between 6-12 months following FT indicates residual disease. The present study assesses the incidence and oncologic implications of early CE observed following primary partial gland cryoablation (PPGCA).
Material and methods: The surveillance protocol for men enrolled in our prospective outcomes study following PPGCA included mpMRI at 6-12 months, 2 years, 3.5 years,… More >

Jean-Baptiste Lattouf¹, Jenny J. Ko², Margot K. Davis³, Christian Constance⁴, Geoffrey T. Gotto⁵

Canadian Journal of Urology, Vol.31, No.5, pp. 11977-11985, 2024

Abstract Introduction: Niraparib, a PARP1/2 inhibitor, is newly approved in combination with abiraterone acetate (AA) plus prednisone or prednisolone (niraparib/AA+P) for the treatment of adult patients with BRCA-mutated, treatment-naïve metastatic castration resistant prostate cancer (mCRPC). Detailed guidance beyond the prescribing information may be helpful in managing the side effect profile and dosing practicalities of this combination therapy.
Materials and methods: A panel of specialists convened to design management algorithms for four common niraparib/ AA+P treatment-related adverse events (AEs) in mCRPC; anemia, thrombocytopenia, hypertension, and nausea. The algorithms build on Health Canada-approved prescribing information to highlight practical considerations related… More >

HUANGLIN DUAN^1,*, BAISHENG XU^1,#, TIANPENG XIE^2,#

BIOCELL, Vol.48, No.12, pp. 1703-1719, 2024, DOI:10.32604/biocell.2024.054873 - 30 December 2024

Abstract Prostate cancer is one of the most common tumors in urology. Dietary prophylaxis can effectively reduce prostate cancer incidence and progression. A growing body of research has shown that natural food ingredients such as Sulforaphane (SFN) can reduce the incidence of prostate cancer. It has a significant inhibitory effect on the progression from local prostate cancer to more aggressive prostate cancer. This article mainly expounds on the prevention mechanism and research progress of sulforaphane in various ways for prostate cancer and provides a reference for its future clinical application. In this review, ‘SFN’, ‘Prostate Cancer’,… More >

Kouamé Konan Yvon Kouassi^1,*, Bitti Adde Odo¹, Yenahaban Lazare Toure¹, Ouowene Prisca Marina Sougue², Petiori Gningayou Laurence épouse Kamara Touré¹, N’Guessan Manlan Prosper Mebiala¹, Fleur Audrey Sessegnon¹, Marie Sandrine Koffi¹, Akissi Marie Barbara Yvonne Nogbou¹, Sherif Traore¹, Asmaho Akissi Danielle Andree Traore-Kouassi¹, Moctar Toure¹

Psycho-Oncologie, Vol.18, No.4, pp. 359-365, 2024, DOI:10.32604/po.2024.049816 - 04 December 2024

Abstract Objective: To evaluate the attitudes and practices of oncosexology in the management of breast and prostate cancer in Côte d’Ivoire. Methods: A cross-sectional, multicenter, descriptive and analytical survey carried out over 02 months from 1 November to 31 December 2022, among doctors involved in the management of breast and prostate cancer in Côte d’Ivoire. Results: 78 physicians on 114 participated in the study, with a participation rate of 79.5%. Only one doctor discussed the sexual risks associated with cancer with all his patients and 7.7% of doctors said they never broached questions of sexuality with their… More >